Companion Animal Arthritis

Global Companion Animal Arthritis Market to Reach US$4.8 Billion by 2030

The global market for Companion Animal Arthritis estimated at US$3.4 Billion in the year 2024, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Dogs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Cats segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$915.1 Million While China is Forecast to Grow at 9.6% CAGR

The Companion Animal Arthritis market in the U.S. is estimated at US$915.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$979.1 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Companion Animal Arthritis Market - Key Trends & Drivers Summarized

What is Driving the Rise in Companion Animal Arthritis Cases?

Arthritis in companion animals, particularly dogs and cats, has been on the rise due to several factors, including increased pet longevity, obesity prevalence, and greater awareness among pet owners. Veterinary advancements and improved diagnostic capabilities have contributed to the identification of arthritis cases that might have otherwise gone unnoticed. As more households treat pets as family members, the demand for high-quality veterinary care, including arthritis management solutions, has surged significantly. Additionally, the growing geriatric pet population has placed arthritis management at the forefront of veterinary care. Many pet owners are now proactively seeking treatments ranging from traditional pharmaceuticals to holistic therapies. The expansion of companion animal insurance coverage has also made arthritis treatments more accessible, reducing financial barriers for pet owners. This trend is fueling the market’s growth, as companies develop new and improved treatment options for managing osteoarthritis and degenerative joint diseases in pets.

How Are Innovations in Veterinary Medicine Transforming Arthritis Treatment?

Veterinary medicine has seen significant breakthroughs in arthritis treatment, with a shift toward more sophisticated, multi-modal approaches. Non-steroidal anti-inflammatory drugs (NSAIDs) remain a primary treatment option, but there is increasing interest in regenerative medicine, including stem cell therapy and platelet-rich plasma (PRP) treatments. These therapies are gaining traction due to their potential to repair damaged tissues and improve mobility without the side effects associated with long-term NSAID use. The introduction of monoclonal antibodies specifically designed to target pain receptors in arthritic animals marks another significant milestone in the market. These novel biologics offer extended pain relief with fewer adverse reactions compared to traditional pain management methods. Additionally, advancements in nutraceuticals, including omega-3 fatty acids, glucosamine, and chondroitin supplements, are driving growth in the arthritis management segment. Manufacturers are now focusing on developing palatable formulations that encourage compliance among pet owners and ensure optimal therapeutic benefits.

Why Is the Market Seeing a Surge in Non-Pharmaceutical Therapies?

As concerns grow over the long-term use of pharmaceuticals, pet owners and veterinarians alike are increasingly turning to non-pharmaceutical interventions for arthritis management. Hydrotherapy, acupuncture, and therapeutic laser treatments are gaining widespread acceptance as complementary therapies that enhance mobility and reduce discomfort. These approaches are especially popular among owners who seek drug-free alternatives or wish to combine treatments for maximum effectiveness. Furthermore, advancements in wearable technology for pets are playing a crucial role in monitoring mobility and detecting early signs of joint deterioration. Smart collars and activity monitors equipped with AI-driven analytics help veterinarians and pet owners make informed decisions about arthritis management. The availability of home-based rehabilitation programs, including guided physiotherapy sessions via mobile applications, is another emerging trend, making arthritis care more accessible and personalized.

What Are the Key Growth Drivers Fueling Market Expansion?

The growth in the Companion Animal Arthritis market is driven by several factors, including the rising number of aging pets, increased pet humanization, and expanding awareness of arthritis treatment options. The rising trend of premium pet care has led to higher spending on veterinary services, pharmaceuticals, and alternative therapies. Additionally, the growing presence of specialized veterinary clinics and rehabilitation centers is contributing to the accessibility and adoption of advanced arthritis treatments. Technological innovations, particularly in biologics and regenerative medicine, are further propelling market expansion. Companies investing in research and development to create safer and more effective treatment options are seeing strong market penetration. The increasing acceptance of pet insurance, which often covers arthritis treatment costs, is making veterinary care more affordable for pet owners, encouraging higher spending on advanced therapies. Moreover, evolving consumer behavior—marked by an increasing preference for holistic, natural, and preventative healthcare solutions—is reshaping the arthritis treatment landscape. Manufacturers are responding by introducing innovative dietary supplements, functional foods, and novel drug formulations tailored to meet these demands. As awareness continues to grow and treatment options become more sophisticated, the Companion Animal Arthritis market is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Companion Animal Arthritis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Animal Type (Dogs, Cats, Other Animal Types); Indication (Osteoarthritis Indication, Other Indications); Treatment Type (Medications Treatment, Supplements Treatment, Other Treatment Types); Distribution Channel (Veterinary Hospitals and Clinics Distribution Channel, Online Stores Distribution Channel, Retail Pharmacies Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• American Regent, Inc.
• Aratana Therapeutics (a subsidiary of Elanco)
• Boehringer Ingelheim
• Ceva Santé Animale
• Companion Animal Health (a division of Enovis™ Corporation)
• Dechra Pharmaceuticals PLC
• Elanco Animal Health
• Eltech K-Laser s.r.l
• Liquid Health Inc.
• Matsun Nutrition
• NexGen Pharmaceuticals
• Norbrook Laboratories Ltd
• Nutri-Vet, LLC
• Synflex America Inc.
• Thorne Research Inc.
• Vetalogica
• Vetbiolix
• Vetoquinol
• Virbac
• Zoetis

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.